Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arformoterol 15 mcg BID vs 30 mcg QD in COPD
NCT00571428Phase 4Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Nov 2007
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of arformoterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Sumitomo Pharma America. Primary endpoint: Time-Normalized Area Under the Change From Pre-Dose Curve for Forced Expiratory Volume in One Second Measured Over 24 Hours. Started Nov 2007; status: completed.
02
Drugs
arformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00571428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00571428.